Develops drugs for multiple sclerosis and other B-cell diseases.
Jun 2026Revenue $800M/yrExpenses $663M/yr
Reached break-even Oct 2024
Figures by year
When did TG Therapeutics become profitable?
Its revenue passed its expenses in Oct 2024. In the 12 months to Jun 2026, revenue was $800M and expenses $663M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $616M | $493M | $123M |
| Dec 2024 | $329M | $287M | $41.9M |
| Dec 2023 | $234M | $213M | $20.6M |
| Dec 2022 | $2.79M | $221M | −$218M |
| Dec 2021 | $6.69M | $351M | −$345M |
| Dec 2020 | $152K | $274M | −$274M |
| Dec 2019 | $152K | $169M | −$169M |
| Dec 2018 | $152K | $175M | −$174M |
| Dec 2017 | $152K | $119M | −$119M |
| Dec 2016 | $152K | $79.1M | −$79.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.